Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Early Phase 1

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 1(2)

Early Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT03966040Phase 1Completed

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Role: collaborator

NCT02804711Phase 1Completed

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Role: collaborator

NCT02692859Phase 3Completed

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Role: collaborator

NCT02820883Early Phase 1Completed

A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Role: collaborator

All 4 trials loaded